Lilly's pancreatic cancer treatment fails late-stage study

[October 16, 2019]  (Reuters) - Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with a cocktail of chemotherapies did not meet the main goal in a late-stage study.

The trial evaluated Lilly's pegilodecakin plus Folfox, which is a combination of chemotherapy drugs, compared to Folfox alone in patients with metastatic pancreatic cancer.

Lilly gained access to pegilodecakin with its $1.6 billion acquisition of Armo Biosciences.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Shailesh Kuber)

[© 2019 Thomson Reuters. All rights reserved.]

Copyright 2019 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.